Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The results failed to impress investors, leading to an 18% drop in after-hours trading following the 6 January announcement. The stock price plunge continued through the day on 7 January, eventually closing more than 36% lower than the previous day. The company highlighted “clinically meaningful” improvements in symptoms, including reductions in eyeball bulging (proptosis), clinical activity score (CAS) and double vision. In the Phase I/II trial (NCT05683496), seven out of eight patients given a 50 mg loading dose followed by 25 mg weekly administration showed improvement in proptosis within 12 weeks, according to the 6 January company presentation. Acelyrin also emphasised that lonigutamab could be safer than Amgen's Tepezza (teprotumumab) – curre
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- DLL3 Targeted Therapy Market Size DLL3 Drugs Clinical Trials DLL3 Cancer Therapy Market Drugs Approval Insight [Yahoo! Finance]Yahoo! Finance
- Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Wells Fargo & Company from $335.00 to $280.00. They now have an "equal weight" rating on the stock.MarketBeat
- Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEPR Newswire
AMGN
Earnings
- 10/30/24 - Beat
AMGN
Sec Filings
- 12/6/24 - Form 4
- 12/3/24 - Form 4
- 11/6/24 - Form 4
- AMGN's page on the SEC website